Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genedx Holdings Corp (WGS)

Genedx Holdings Corp (WGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,517,048
  • Shares Outstanding, K 28,905
  • Annual Sales, $ 305,450 K
  • Annual Income, $ -52,290 K
  • EBIT $ 10 M
  • EBITDA $ 32 M
  • 60-Month Beta 2.01
  • Price/Sales 6.13
  • Price/Cash Flow 80.19
  • Price/Book 8.12

Options Overview Details

View History
  • Implied Volatility 72.47% (+1.96%)
  • Historical Volatility 81.16%
  • IV Percentile 45%
  • IV Rank 18.34%
  • IV High 157.37% on 04/07/25
  • IV Low 53.41% on 08/28/25
  • Expected Move (DTE 3) 3.93 (4.87%)
  • Put/Call Vol Ratio 1.02
  • Today's Volume 839
  • Volume Avg (30-Day) 1,474
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 13,234
  • Open Int (30-Day) 16,266
  • Expected Range 76.77 to 84.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -132.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.01 +2.14%
on 02/23/26
106.76 -24.41%
on 01/27/26
-20.65 (-20.37%)
since 01/23/26
3-Month
79.01 +2.14%
on 02/23/26
170.87 -52.77%
on 12/02/25
-80.38 (-49.90%)
since 11/24/25
52-Week
55.17 +46.28%
on 05/08/25
170.87 -52.77%
on 12/02/25
-14.30 (-15.05%)
since 02/24/25

Most Recent Stories

More News
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) ...

WGS : 80.70 (-7.33%)
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health

Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes

WGS : 80.70 (-7.33%)
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens...

WGS : 80.70 (-7.33%)
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

WGS : 80.70 (-7.33%)
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025...

WGS : 80.70 (-7.33%)
GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GeneDx’s Infinity™ will leverage insights from Komodo’s Healthcare Map ® to unlock faster health economics and outcomes research (HEOR), biopharma innovation,...

WGS : 80.70 (-7.33%)
GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

New whole genome sequencing test delivers fast, comprehensive insights when fetal anomalies are identified, reinforcing GeneDx’s commitment to enabling precise, fast, and actionable rare disease diagnosis...

WGS : 80.70 (-7.33%)
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare

WGS : 80.70 (-7.33%)
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

Industry-leading research powered by GeneDx Infinity™ accelerates the transition of genomics from discovery to the standard of clinical care, driving better outcomes for patients across healthcare settings...

WGS : 80.70 (-7.33%)
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference...

WGS : 80.70 (-7.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.

See More

Key Turning Points

3rd Resistance Point 89.17
2nd Resistance Point 87.25
1st Resistance Point 83.98
Last Price 80.70
1st Support Level 78.79
2nd Support Level 76.87
3rd Support Level 73.59

See More

52-Week High 170.87
Fibonacci 61.8% 126.67
Fibonacci 50% 113.02
Fibonacci 38.2% 99.37
Last Price 80.70
52-Week Low 55.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar